Vesalius Biocapital and Capricorn Venture Partners lead Series B round for TROD Medical

Medical device company TROD Medical NV/SA said Thursday that it has closed 4.75 million euros in Series B financing. Vesalius Biocapital and Capricorn Venture Partners co-led the round. Other investors included Gemma Frisius Fund, the spin-off fund of the University of Leuven and the Flemish investment firm PMV. As part of the financing, TROD Medical has relocated its headquarters to Leuven, Belgium. Also, TROD Medical has named Frank Bulens of Capricorn Venture Partners and Stéphane Verdood of Vesalius BioCapital to the company's board of directors.

North AmericaUSBriefs